https://www.nasdaq.com/press-release/athenex-to-host-a-kol-webinar-today-on-car-nkt-cell-approach-to-cancer-and-latest
https://www.nasdaq.com/press-release/athenex-to-host-key-opinion-leader-webinar-on-car-nkt-approach-to-cancer-2021-11-30
https://www.nasdaq.com/press-release/athenex-announces-uk-mhra-validation-of-the-marketing-authorization-application-for
https://www.nasdaq.com/press-release/athenex-to-present-subgroup-analysis-from-phase-3-study-of-oral-paclitaxel-plus
https://www.nasdaq.com/press-release/athenex-to-present-at-the-evercore-isi-4th-annual-healthconx-conference-2021-11-18
https://www.nasdaq.com/press-release/athenex-announces-exclusive-license-agreement-with-national-cancer-institute-to
https://www.nasdaq.com/press-release/athenex-presents-interim-data-from-anchor-study-of-kur-502-allogeneic-cd19-car-nkt
https://www.nasdaq.com/press-release/athenex-provides-third-quarter-2021-corporate-and-financial-update-2021-11-04
https://www.nasdaq.com/press-release/athenex-to-provide-corporate-and-financial-update-for-the-third-quarter-2021-on-0
https://www.nasdaq.com/press-release/athenex-to-provide-corporate-and-financial-update-for-the-third-quarter-2021-on
https://www.nasdaq.com/press-release/athenex-and-the-center-for-cell-and-gene-therapy-announce-allowance-of-our-first-u.s.
https://www.nasdaq.com/press-release/athenex-provides-update-from-fda-type-a-meeting-regarding-oral-paclitaxel-encequidar
https://www.nasdaq.com/press-release/athenex-announces-phased-european-launch-of-klisyrir-tirbanibulin-for-the-treatment
https://www.nasdaq.com/press-release/athenex-presents-data-from-oral-paclitaxel-pembrolizumab-phase-1-study-at-esmo-2021
https://www.nasdaq.com/press-release/athenex-to-present-at-the-oppenheimer-2021-fall-healthcare-life-sciences-med-tech
https://www.nasdaq.com/press-release/athenex-provides-second-quarter-2021-corporate-and-financial-update-2021-08-05
https://www.nasdaq.com/press-release/athenex-announces-additional-licensing-agreements-for-tirbanibulin-2021-07-26
https://www.nasdaq.com/press-release/athenex-to-provide-corporate-and-financial-update-for-the-second-quarter-2021-on
https://www.nasdaq.com/press-release/athenex-announces-european-commission-approval-of-klisyrir-tirbanibulin-for-the
https://www.nasdaq.com/press-release/athenex-provides-update-from-fda-type-a-meeting-regarding-oral-paclitaxel-plus
https://www.nasdaq.com/press-release/athenex-presents-data-on-oral-docetaxel-and-oral-paclitaxel-at-asco2021-virtual
https://www.nasdaq.com/press-release/athenex-announces-klisyrir-tirbanibulin-receives-positive-chmp-opinion-from-the
https://www.nasdaq.com/press-release/athenex-texas-childrens-cancer-center-and-the-center-for-cell-and-gene-therapy-at
https://www.nasdaq.com/press-release/athenex-provides-first-quarter-2021-corporate-and-financial-update-2021-05-06
https://www.nasdaq.com/press-release/athenex-to-acquire-kuur-therapeutics-to-expand-cell-therapy-development-with-off-the
https://www.nasdaq.com/press-release/athenex-to-provide-corporate-and-financial-update-for-the-first-quarter-2021-on-may-6
https://www.nasdaq.com/press-release/lawsuit-filed%3a-block-leviton-llp-has-filed-a-lawsuit-against-athenex-inc.-for
https://www.nasdaq.com/press-release/notice-of-lead-plaintiff-deadline-for-shareholders-in-the-athenex-inc.-class-action
https://www.nasdaq.com/press-release/athenex-provides-fourth-quarter-and-full-year-2020-corporate-and-financial-update
https://www.nasdaq.com/press-release/athenex-receives-fda-complete-response-letter-for-oral-paclitaxel-plus-encequidar-for
https://www.nasdaq.com/press-release/athenex-to-provide-a-corporate-and-financial-update-for-the-fourth-quarter-and-full
https://www.nasdaq.com/press-release/athenex-announces-u.s.-launch-of-klisyrir-and-licensing-of-additional-territories-for
https://www.nasdaq.com/press-release/almirall-u.s.-launches-klisyrir-tirbanibulin-a-new-innovative-topical-treatment-for
https://www.nasdaq.com/press-release/athenex-announces-new-england-journal-of-medicine-publication-of-phase-iii-data-on
https://www.nasdaq.com/press-release/almirall-announces-new-england-journal-of-medicine-publication-of-phase-iii-data
https://www.nasdaq.com/press-release/ceo-dr.-johnson-lau-recuperating-from-covid-at-home-2021-01-25
https://www.nasdaq.com/press-release/ceo-dr.-johnson-lau-contracts-covid-19-2021-01-08
https://www.nasdaq.com/press-release/athenex-to-present-at-the-39th-annual-j.p.-morgan-healthcare-conference-2021-01-05
https://www.nasdaq.com/press-release/athenex-announces-fda-approval-of-klisyrir-tirbanibulin-for-the-treatment-of-actinic
https://www.nasdaq.com/press-release/almirall-announces-fda-approval-of-klisyrir-tirbanibulin-a-new-innovative-topical
https://www.nasdaq.com/press-release/athenex-presents-updated-phase-3-data-on-survival-and-tolerability-associated-with
https://www.nasdaq.com/press-release/athenex-pharmaceutical-division-and-ingenus-pharmaceuticals-announce-availability-of
https://www.nasdaq.com/press-release/athenex-announces-data-on-oral-paclitaxel-and-encequidar-to-be-presented-at-the-2020
https://www.nasdaq.com/press-release/athenex-inc.-reports-third-quarter-ended-september-30-2020-financial-results-and
https://www.nasdaq.com/press-release/athenex-inc.-to-report-third-quarter-2020-earnings-results-on-november-5-2020-2020-10
https://www.nasdaq.com/press-release/axis-therapeutics-announces-research-collaboration-with-pharmaessentia-for
https://www.nasdaq.com/press-release/athenex-oncology-launches-your-guide-to-facing-metastatic-breast-cancer-a-first-of
https://www.nasdaq.com/press-release/athenex-announces-fda-allowance-of-ind-application-for-tcrt-eso-a2-a-tcr-t-cell
https://www.nasdaq.com/press-release/athenex-inc.-announces-pricing-of-%24110-million-public-offering-of-common-stock-2020
https://www.nasdaq.com/press-release/athenex-inc.-announces-proposed-public-offering-of-common-stock-2020-09-08
https://www.nasdaq.com/press-release/quantum-leap-healthcare-collaborative-and-athenex-announce-the-selection-of-oral
https://www.nasdaq.com/press-release/athenex-announces-fda-acceptance-for-filing-of-u.s.-nda-for-oral-paclitaxel-and
https://www.nasdaq.com/press-release/athenex-announces-%2450-million-revenue-interest-financing-with-sagard-healthcare
https://www.nasdaq.com/press-release/athenex-inc.-reports-second-quarter-ended-june-30-2020-financial-results-and-provides
https://www.nasdaq.com/press-release/biopharmaceutical-leader-robert-j.-spiegel-md-facp-appointed-to-the-athenex-board-of
https://www.nasdaq.com/press-release/athenex-inc.-to-report-second-quarter-2020-earnings-results-on-august-6-2020-2020-07
https://www.nasdaq.com/press-release/athenex-appoints-teresa-bair-esq.-as-executive-officer-and-general-counsel-2020-06-23
https://www.nasdaq.com/press-release/athenex-announces-%24225-million-loan-agreement-with-oaktree-2020-06-22
https://www.nasdaq.com/press-release/athenex-presents-interim-data-from-oral-paclitaxel-phase-ii-study-in-cutaneous
https://www.nasdaq.com/press-release/athenex-announces-participation-in-the-2020-rbc-capital-markets-global-healthcare
https://www.nasdaq.com/press-release/athenex-inc.-reports-first-quarter-ended-march-31-2020-financial-results-and-provides
https://www.nasdaq.com/press-release/athenex-announces-acceptance-of-oral-paclitaxel-phase-ii-study-in-angiosarcoma
https://www.nasdaq.com/press-release/athenex-inc.-to-report-first-quarter-2020-earnings-results-on-may-7-2020-2020-04-23
https://www.nasdaq.com/press-release/athenex-provides-an-update-on-oral-paclitaxel-fda-meeting-2020-04-09
https://www.nasdaq.com/press-release/athenex-provides-a-corporate-update-2020-03-13
https://www.nasdaq.com/press-release/athenex-announces-fda-acceptance-for-filing-of-u.s.-nda-for-tirbanibulin-ointment-in
https://www.nasdaq.com/press-release/athenexs-partner-almirall-announces-ema-acceptance-for-filing-of-marketing
https://www.nasdaq.com/press-release/athenex-inc.-reports-fourth-quarter-and-year-ended-december-31-2019-financial-results
https://www.nasdaq.com/press-release/athenex-announces-participation-at-the-cowen-40th-annual-health-care-conference-2020
https://www.nasdaq.com/press-release/athenex-inc.-to-report-fourth-quarter-and-full-year-2019-earnings-results-on-february
https://www.nasdaq.com/press-release/athenex-ceo-informs-shareholders-of-unrelated-matter-regarding-past-board-membership
https://www.nasdaq.com/press-release/athenex-expands-its-strategic-partnership-with-guangzhou-xiangxue-pharmaceutical
https://www.nasdaq.com/press-release/faruqi-faruqi-llp-is-investigating-athenex-inc.-atnx-on-behalf-of-its-shareholders
https://www.nasdaq.com/press-release/athenex-announces-superior-response-and-survival-with-lower-neuropathy-of-a-novel
https://www.nasdaq.com/press-release/athenex-announces-details-of-investor-event-and-webcast-at-sabcs-on-december-13-2019
https://www.nasdaq.com/press-release/athenex-announces-%2460-million-private-placement-2019-12-05
https://www.nasdaq.com/press-release/athenex-announces-key-company-activities-at-san-antonio-breast-cancer-symposium-2019
https://www.nasdaq.com/press-release/athenex-inc.-announces-third-quarter-2019-financial-results-2019-11-07
https://www.nasdaq.com/press-release/athenex-announces-european-commission-grants-orphan-designations-for-paclitaxel-and
https://www.nasdaq.com/press-release/athenex-announces-progress-update-from-partner-almirall-on-tirbanibulin-ointment-2019
https://www.nasdaq.com/press-release/athenex-inc.-to-report-third-quarter-2019-earnings-results-on-november-7-2019-2019-10
https://www.nasdaq.com/press-release/athenex-provides-an-update-to-shareholders-2019-10-24
https://www.nasdaq.com/press-release/athenex-to-highlight-oral-paclitaxel-clinical-programs-targeting-various-solid-tumors
https://www.nasdaq.com/press-release/athenex-completes-construction-of-new-api-facility-in-chongqing-2019-09-23
https://www.nasdaq.com/press-release/athenex-to-present-at-the-2019-san-antonio-breast-cancer-symposium-2019-09-23
https://www.nasdaq.com/press-release/athenex-announces-initiation-of-phase-i-clinical-study-in-china-of-kx2-361-oral-by
https://www.nasdaq.com/press-release/athenex-inc-announces-fourth-quarter-and-year-ended-december-31-2018-financial
https://www.nasdaq.com/press-release/athenex-present-preclinical-data-oraxol-treatment-angiosarcoma-american-association
